trending Market Intelligence /marketintelligence/en/news-insights/trending/PSGUeXWycpDE74ILq2fagQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Billionaire shareholders combine stake in Santhera with Iglu's

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Billionaire shareholders combine stake in Santhera with Iglu's

Santhera Pharmaceuticals Holding AG said the Bertarelli Group combined its ownership in the company with that of the Iglu Group to form a new shareholder group.

The collective now owns 1,179,977 shares of the company, representing 18.84% of Santhera. The Bertarelli Group previously owned 8.71% of the company with the remaining 10.13% under Iglu's control.

The Bertarelli Group represents billionaires Ernesto Bertarelli, Donata Guichard-Bertarelli and Maria-Iris Bertarelli who inherited Serono, a Swiss biotech which was sold to Merck KGaA in 2006 for €10.6 billion.

Santhera itself is a Swiss pharmaceutical company whose lead product, Raxone, is authorized in the EU, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy, an eye disease.

Raxone is also being developed for the treatment of Duchenne muscular dystrophy and primary progressive multiple sclerosis.

In an emailed response to S&P Global Market Intelligence, Santhera CEO Thomas Meier said that both groups had been shareholders of the company for several years.

"We will certainly speak with representatives of this new shareholder group over the coming days but, given the regular and positive interactions we had over the past years with both groups, I am confident that this new group will continue to support the management and the company in its ambitions for the future," Meier said.